[go: up one dir, main page]

MX2018004022A - Composiciones y metodos para unir dominios extracelulares de tipo i y tipo ii como proteinas quimericas heterologas. - Google Patents

Composiciones y metodos para unir dominios extracelulares de tipo i y tipo ii como proteinas quimericas heterologas.

Info

Publication number
MX2018004022A
MX2018004022A MX2018004022A MX2018004022A MX2018004022A MX 2018004022 A MX2018004022 A MX 2018004022A MX 2018004022 A MX2018004022 A MX 2018004022A MX 2018004022 A MX2018004022 A MX 2018004022A MX 2018004022 A MX2018004022 A MX 2018004022A
Authority
MX
Mexico
Prior art keywords
type
compositions
methods
extracellular domains
chimeric proteins
Prior art date
Application number
MX2018004022A
Other languages
English (en)
Other versions
MX389750B (es
Inventor
Fromm George
schreiber Taylor
SCHILLING Neal
De Silva Suresh
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of MX2018004022A publication Critical patent/MX2018004022A/es
Publication of MX389750B publication Critical patent/MX389750B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion hace referencia a composiciones y metodos que incluyen proteinas quimericas utiles en el tratamiento de enfermedades, como inmunoterapias para el cancer y la autoinmunidad, entre otras cosas. En parte, la invencion brinda, en diversas modalidades, fusiones de dominios extracelulares de proteinas transmembrana que pueden tener efectos inhibidores o estimuladores.
MX2018004022A 2015-10-01 2016-09-30 Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas. MX389750B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235727P 2015-10-01 2015-10-01
US201562263313P 2015-12-04 2015-12-04
US201662372574P 2016-08-09 2016-08-09
PCT/US2016/054598 WO2017059168A1 (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Publications (2)

Publication Number Publication Date
MX2018004022A true MX2018004022A (es) 2018-09-11
MX389750B MX389750B (es) 2025-03-20

Family

ID=58424302

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004022A MX389750B (es) 2015-10-01 2016-09-30 Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
MX2022001299A MX2022001299A (es) 2015-10-01 2018-03-28 Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001299A MX2022001299A (es) 2015-10-01 2018-03-28 Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.

Country Status (16)

Country Link
US (14) US10183060B2 (es)
EP (2) EP4183451B1 (es)
JP (3) JP6981973B2 (es)
KR (1) KR20180051651A (es)
CN (3) CN116063567A (es)
AU (3) AU2016331076B2 (es)
BR (1) BR112018006578A2 (es)
CA (1) CA2999280A1 (es)
IL (4) IL303586B2 (es)
MX (2) MX389750B (es)
PH (1) PH12018500694A1 (es)
RU (2) RU2022102624A (es)
SA (1) SA518391219B1 (es)
SG (5) SG10201913597VA (es)
UA (1) UA126549C2 (es)
WO (1) WO2017059168A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113747947A (zh) * 2019-02-28 2021-12-03 沙塔克实验室有限公司 组合疗法

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2018127918A1 (en) * 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirp alpha-cd70 fusion protein and methods of use thereof
WO2018127916A1 (en) * 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
WO2018127917A1 (en) * 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
DK3565828T3 (da) 2017-01-05 2022-02-21 Kahr Medical Ltd Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
BR112019017713A2 (pt) * 2017-02-27 2020-04-07 Shattuck Labs Inc proteínas quiméricas à base de csf1r
WO2018157163A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
MY207687A (en) 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CA3094886A1 (en) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
KR20180120893A (ko) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도
RU2771110C2 (ru) * 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
CN109646678A (zh) * 2017-10-12 2019-04-19 中国科学院上海生命科学研究院 Sun2蛋白、其制药用途及药物
CN108384795A (zh) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 作用于tme免疫效应细胞的人工合成基因及验证方法和应用
CN117106096A (zh) * 2017-10-26 2023-11-24 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
CN111601823B (zh) * 2017-11-07 2024-09-24 德克萨斯大学体系董事会 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
WO2019136316A1 (en) * 2018-01-04 2019-07-11 Washington University Compositions and methods for inhibition of alphavirus infection
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
EP3795585A4 (en) * 2018-05-16 2022-03-16 Genome and Company Pharmaceutical composition for preventing or treating cancer comprising lrit2 inhibitor as active ingredient
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
BR112020026112A2 (pt) * 2018-06-21 2021-04-06 Shattuck Labs, Inc. Proteínas heterodiméricas e usos das mesmas
CA3104780A1 (en) * 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
SG11202013170RA (en) * 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
CN112912384A (zh) * 2018-08-29 2021-06-04 沙塔克实验室有限公司 组合疗法
MX2021002294A (es) 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
MX2021002289A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Proteinas quimericas basadas en flt3l.
CA3109349A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
CN109053902B (zh) * 2018-09-11 2021-06-15 河南科技大学 一种嵌合蛋白aqp4-ch2、制备及其应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3893888A4 (en) * 2018-12-10 2022-08-31 Bioxcel Therapeutics, Inc. COMBINATION THERAPIES FOR TREATING DISEASES USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST
WO2020127369A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
WO2020142815A1 (en) * 2019-01-07 2020-07-16 Celluris Participações Ltda Bispecific in tandem receptor car and method for modulating the tumoral microenvironment
MX2021008022A (es) * 2019-01-07 2021-08-05 Shattuck Labs Inc Proteínas heterodiméricas para modular células t gamma delta.
AU2020208192A1 (en) * 2019-01-14 2021-08-05 Regents Of The University Of Minnesota CD200AR ligands for cancer immunotherapy
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
JP2022532430A (ja) * 2019-05-16 2022-07-14 シャタック ラボ，インコーポレイテッド Ｎｋ細胞指向性キメラタンパク質
JP2022537066A (ja) * 2019-06-21 2022-08-23 シャタック ラボ，インコーポレイテッド キメラタンパク質を発現するｔ細胞
AU2020311636A1 (en) * 2019-07-11 2022-03-03 Kahr Medical Ltd. Heterodimers and methods of use thereof
US20220289822A1 (en) * 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2020340424A1 (en) * 2019-08-30 2022-03-31 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
CN110592172B (zh) * 2019-10-29 2021-05-28 华中农业大学 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点
KR20220101151A (ko) * 2019-11-14 2022-07-19 루드비히 인스티튜트 포 캔서 리서치 리미티드 면역치료요법을 위한 조성물 및 방법
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN111849913B (zh) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 工程化免疫细胞及其用途
EP4232065A4 (en) * 2020-10-26 2024-10-16 Shattuck Labs, Inc. HOMODIMERIC AND HETERODIMERIC PROTEINS COMPRISING BUTYROPHILIN
WO2022094482A1 (en) * 2020-11-02 2022-05-05 Athae Bio, Inc. Two-domain multimeric fusion proteins
CA3201215A1 (en) * 2020-12-03 2022-06-09 Taylor Schreiber Method of determining resistance to checkpoint inhibitor therapies
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
JP2024508540A (ja) * 2021-03-05 2024-02-27 シャタック ラボ，インコーポレイテッド ＳＩＲＰαベースのキメラタンパク質を用いた併用療法
WO2022187583A1 (en) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Combination therapies with tim-3-based chimeric proteins
KR20220138909A (ko) * 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
US20250092143A1 (en) * 2021-07-23 2025-03-20 University Of Southern California Genetically engineered multifunctional exosomes for immunotherapy
WO2023019251A1 (en) * 2021-08-12 2023-02-16 Baylor College Of Medicine Engineered soluble decoy receptors to enhance cancer immunotherapy
CA3236824A1 (en) * 2021-11-01 2023-05-04 Taylor Schreiber Modified mrna therapeutics
JP2025500456A (ja) * 2021-12-23 2025-01-09 カール メディカル リミテッド Ｌｉｌｒｂポリペプチド及びその使用
CN118946347A (zh) * 2022-01-20 2024-11-12 埃克索丘尔瑞典公司 表达膜蛋白的重组细胞系及由其制备的囊泡
JP2025522824A (ja) * 2022-07-01 2025-07-17 フェイト セラピューティクス，インコーポレイティド 養子細胞療法におけるエフェクター細胞の耐久性及び有効性の増強
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用
CN120721960B (zh) * 2025-08-19 2025-11-21 上海金域医学检验所有限公司 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1993023431A1 (en) 1992-05-14 1993-11-25 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
AU2926401A (en) 2000-01-03 2001-07-16 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
WO2003042402A2 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP3020413A1 (en) * 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
NZ543654A (en) * 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
CA2541006C (en) * 2003-10-03 2015-02-17 Brigham And Women's Hospital Tim-3 polypeptides
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
MXPA06014126A (es) * 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2652570A1 (en) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
CA2656923A1 (en) * 2006-06-21 2007-12-27 Genentech, Inc. Crystal structures of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
FI3056514T4 (fi) 2008-01-15 2025-10-06 Univ Leland Stanford Junior Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
AU2009233708B2 (en) * 2008-04-09 2015-06-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CN102137869B (zh) 2008-06-30 2018-07-06 宾夕法尼亚大学 Fn14/TRAIL融合蛋白
EP2310508A1 (en) 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tgf-b antagonist multi-target binding proteins
CN102227447A (zh) * 2008-10-02 2011-10-26 新兴产品开发西雅图有限公司 Cd86拮抗物多靶点结合蛋白
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
JP2012512640A (ja) * 2008-12-19 2012-06-07 ノバルティス アーゲー 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
US20130011401A1 (en) * 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
DK2542590T4 (da) * 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
CN103261217B (zh) 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
ES2676499T3 (es) * 2011-04-13 2018-07-20 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
PH12014500247A1 (en) 2011-07-29 2014-03-24 Univ Pennsylvania Switch costimulatory receptors
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
CN104334573A (zh) * 2012-04-30 2015-02-04 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
EP4053162A1 (en) 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
CN104602707A (zh) 2012-06-06 2015-05-06 昂考梅德药品有限公司 调节hippo途径的结合剂及其应用
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2013362789B8 (en) 2012-12-17 2018-08-02 Pfizer Inc. Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions
WO2014106839A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
CN113684185A (zh) * 2013-02-26 2021-11-23 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
PL2970512T3 (pl) 2013-03-12 2019-03-29 Biocon Limited Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
IL296026B2 (en) * 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
KR20160065925A (ko) * 2013-10-15 2016-06-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 응고 인자 vii 폴리펩티드
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
CN106102774A (zh) 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
JP2017501157A (ja) * 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
CN106459218B (zh) * 2014-03-24 2021-03-02 宜明昂科生物医药技术（上海）有限公司 新的重组双功能融合蛋白、其制剂和用途
US9718870B2 (en) 2014-05-29 2017-08-01 Medimmune, Llc OX40L fusion proteins and uses thereof
WO2015200828A1 (en) 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
CN106535914B (zh) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
MX377196B (es) 2014-08-15 2025-03-07 Merck Patent Gmbh Proteinas de fusion de inmunoglobulina de la proteina alfa reguladora de señal (sirp-alfa).
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
CA2974807A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
ES2857109T3 (es) 2015-05-18 2021-09-28 Ab Initio Biotherapeutics Inc Composiciones polipeptídicas de SIRP y métodos de uso
IL256989B (en) 2015-08-07 2022-08-01 Alx Oncology Inc Constructs with a sirp-alpha site or a variant thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113747947A (zh) * 2019-02-28 2021-12-03 沙塔克实验室有限公司 组合疗法

Also Published As

Publication number Publication date
CN116063566A (zh) 2023-05-05
MX2022001299A (es) 2022-05-10
US20180326006A1 (en) 2018-11-15
CN108350055A (zh) 2018-07-31
WO2017059168A1 (en) 2017-04-06
AU2016331076A1 (en) 2018-04-05
CN108350055B (zh) 2022-11-08
AU2021200367B2 (en) 2024-05-02
AU2016331076B2 (en) 2020-12-03
US20250332219A1 (en) 2025-10-30
KR20180051651A (ko) 2018-05-16
HK1258835A1 (zh) 2019-11-22
JP2021168699A (ja) 2021-10-28
US20170095531A1 (en) 2017-04-06
IL258029B (en) 2022-09-01
US10449233B2 (en) 2019-10-22
AU2021200367C1 (en) 2024-05-30
US20180326004A1 (en) 2018-11-15
IL258029A (en) 2018-05-31
SG10201913597VA (en) 2020-02-27
US10183060B2 (en) 2019-01-22
US20200101136A1 (en) 2020-04-02
CN116063567A (zh) 2023-05-05
US10493128B2 (en) 2019-12-03
EP3356393A4 (en) 2019-08-07
US20200246431A1 (en) 2020-08-06
EP4183451A1 (en) 2023-05-24
US20180326008A1 (en) 2018-11-15
US10086042B2 (en) 2018-10-02
PH12018500694A1 (en) 2018-10-01
US10188701B2 (en) 2019-01-29
IL303586A (en) 2023-08-01
US20180326007A1 (en) 2018-11-15
UA126549C2 (uk) 2022-11-02
IL316210A (en) 2024-12-01
IL295423B1 (en) 2023-07-01
EP4183451B1 (en) 2024-11-27
IL295423B2 (en) 2023-11-01
US20200261537A1 (en) 2020-08-20
IL303586B1 (en) 2024-11-01
JP2018529363A (ja) 2018-10-11
IL303586B2 (en) 2025-03-01
US20180064787A1 (en) 2018-03-08
RU2766200C1 (ru) 2022-02-09
AU2021200367A1 (en) 2021-03-18
US10660936B2 (en) 2020-05-26
US10653748B2 (en) 2020-05-19
SG10201913576RA (en) 2020-02-27
IL295423A (en) 2022-10-01
JP6981973B2 (ja) 2021-12-17
EP3356393A1 (en) 2018-08-08
US10525102B2 (en) 2020-01-07
US11547742B1 (en) 2023-01-10
CA2999280A1 (en) 2017-04-06
US10543253B2 (en) 2020-01-28
US10646545B2 (en) 2020-05-12
JP7303254B2 (ja) 2023-07-04
US20180326005A1 (en) 2018-11-15
JP2023112132A (ja) 2023-08-10
SG10201913573UA (en) 2020-03-30
RU2022102624A (ru) 2022-03-10
US20190151413A1 (en) 2019-05-23
BR112018006578A2 (pt) 2018-12-26
SG10201913591SA (en) 2020-02-27
SG11201801984TA (en) 2018-04-27
US20180125935A1 (en) 2018-05-10
SA518391219B1 (ar) 2022-11-30
MX389750B (es) 2025-03-20
US12178847B2 (en) 2024-12-31
AU2024202253A1 (en) 2024-05-16
US11654180B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
PH12018500694A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
ZA201905488B (en) Tigit- and light-based chimeric proteins
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
NZ749279A (en) Compositions and methods related to engineered fc constructs
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12019501534A1 (en) Csf1r-based chimeric proteins
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2021002289A (es) Proteinas quimericas basadas en flt3l.
MX2021002286A (es) Terapias de combinacion.